HOWL
NASDAQWerewolf Therapeutics Inc.
Price$0.38-0.03 (-7.54%)
01:30 PM07:45 PM
News · 26 weeks92-53%
2025-12-142026-06-07
Mix5790d
- SEC Filings40(70%)
- Insider12(21%)
- Other5(9%)
Latest news
25 items- INSIDERDirector Evnin Luke sold $43,029 worth of shares (105,565 units at $0.41) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- INSIDERDirector Evnin Luke sold $63,628 worth of shares (139,803 units at $0.46) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- INSIDERDirector Evnin Luke sold $66,200 worth of shares (141,106 units at $0.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- INSIDERDirector Evnin Luke sold $86,560 worth of shares (191,762 units at $0.45) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- INSIDERDirector Evnin Luke sold $76,363 worth of shares (171,049 units at $0.45) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Werewolf Therapeutics Inc.SCHEDULE 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- INSIDERDirector Evnin Luke sold $24,127 worth of shares (44,679 units at $0.54) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Werewolf Therapeutics Inc.SCHEDULE 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- INSIDERDirector Evnin Luke sold $280,210 worth of shares (407,574 units at $0.69) as part of a pre-agreed trading plan (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- INSIDERLarge owner Ra Capital Management, L.P. sold $390,688 worth of shares (565,167 units at $0.69) (SEC Form 4)4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
- SECSEC Form 144 filed by Werewolf Therapeutics Inc.144 - Werewolf Therapeutics, Inc. (0001785530) (Subject)
HOWL FAQ
7 questionsWhat does Werewolf Therapeutics Inc. do?
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or...Where does HOWL stock trade?
Werewolf Therapeutics Inc. (HOWL) is listed on NASDAQ.What sector and industry is HOWL in?
Werewolf Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Werewolf Therapeutics Inc. go public?
Werewolf Therapeutics Inc. (HOWL) completed its IPO in 2021.What are analysts saying about HOWL?
Werewolf Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Wedbush: Neutral with a $100.00 price target on 2025-12-19.What companies are similar to HOWL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare HOWL side-by-side with any of them on Quantisnow.How can I track HOWL on Quantisnow?
Quantisnow aggregates Werewolf Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HOWL to receive live email and push alerts on every new disclosure.